FGFR1 and non-small cell lung carcinoma: In both studies, ~ 11% of patients with FGFR1-amplified Sq-NSCLC achieved PR (4/36 and 3/26, respectively) with a decrease in tumor size of ~ 30–40%, and ~ 40% of patients had SD.